The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis
暂无分享,去创建一个
E. Granieri | G. Comi | M. Trojano | G. Savettieri | P. Livrea | G. Rosati | D. Paolicelli | A. Fuiani | E. Di Monte | P. Russo
[1] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[2] P. Bramanti,et al. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. , 2004, Journal of evaluation in clinical practice.
[3] V. Martinelli,et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients , 2003, Journal of neurology, neurosurgery, and psychiatry.
[4] M. Trojano,et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy , 2003, Multiple sclerosis.
[5] S. Vukusic,et al. Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.
[6] C. Granger,et al. Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium , 2003, Multiple sclerosis.
[7] L. Munari,et al. Interferons in relapsing remitting multiple sclerosis : a systematic review , 2022 .
[8] Maria Liguori,et al. Age‐related disability in multiple sclerosis , 2002, Annals of neurology.
[9] M. Lauer,et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. , 2001, JAMA.
[10] E. Celius,et al. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25‐year period , 2001, European journal of neurology.
[11] S. Rasmussen,et al. The Danish Multiple Sclerosis Registry. History, data collection and validity. , 2001, Danish medical bulletin.
[12] L. Wallentin,et al. Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.
[13] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.
[14] J. Concato,et al. Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.
[15] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.
[16] T. Vollmer,et al. The NARCOMS Patient Registry: A Resource for Investigators , 1999 .
[17] B. Weinshenker,et al. Databases in MS research: pitfalls and promises , 1999, Multiple sclerosis.
[18] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[19] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[20] R. P. Kinkel,et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis , 1997, Neurology.
[21] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[22] T. Pincus,et al. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? , 1995, The Journal of rheumatology.
[23] F. Wolfe,et al. Data collection in the clinic. , 1995, Rheumatic diseases clinics of North America.
[24] G. Serio,et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[25] J. E. Rees,et al. A prevalence survey of multiple sclerosis in Sussex. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[26] N. Wood,et al. Multiple sclerosis in the Cambridge health district of east Anglia. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[27] C Confavreux,et al. EDMUS, a European database for multiple sclerosis. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[28] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.
[29] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[30] P H Plotz,et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.
[31] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[32] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[33] R. Califf,et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.
[34] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[35] D. Paty,et al. MS COSTAR: A computerized patient record adapted for clinical research purposes , 1994, Annals of neurology.